Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain

Josep Darbà,1 Lisette Kaskens,2 Francesc Sorio Vilela,3 Mickael Lothgren4 1Department of Economics, Universitat de Barcelona, 2BCN Health Economics and Outcomes Research SL, 3Amgen SA, Barcelona, Spain; 4Amgen (Europe) GmbH, Zug, Switzerland Background: The objective of this study was t...

Full description

Bibliographic Details
Main Authors:	Darbà J, Kaskens L, Sorio Vilela F, Lothgren M
Format:	Article
Language:	English
Published:	Dove Medical Press 2015-02-01
Series:	ClinicoEconomics and Outcomes Research
Online Access:	http://www.dovepress.com/cost-utility-of-denosumab-for-the-treatment-of-postmenopausal-osteopor-peer-reviewed-article-CEOR

Similar Items

Cost-effectiveness of bazedoxifene versus raloxifene in the treatment of postmenopausal women in Spain
by: Darb&agrave; J, et al.
Published: (2013-07-01)

Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
by: Yong-Ki Min
Published: (2015-03-01)

Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
by: Lewiecki EM
Published: (2011-12-01)

Denosumab versus romosozumab for postmenopausal osteoporosis treatment
by: Tomonori Kobayakawa, et al.
Published: (2021-06-01)

The Bisphosphonates versus Denosumab Efficiency in Postmenopausal Osteoporosis Treatment
by: Lorena Ciumărnean, et al.
Published: (2017-05-01)

Denosumab – a new medication in the treatment of postmenopausal osteoporosis
by: Radosław Słopień, et al.
Published: (2017-10-01)

Emerging treatments for postmenopausal osteoporosis – focus on denosumab
by: Piet Geusens
Published: (2009-06-01)

Safety and efficacy of denosumab in postmenopausal somen with osteoporosis
by: Dilsad Sindel, et al.
Published: (2020-10-01)

Denosumab: an investigational drug for the management of postmenopausal osteoporosis
by: E Michael Lewiecki
Published: (2008-08-01)

The effect of denosumab treatment on osteoclast precursor cells in postmenopausal osteoporosis
by: Andreas Fontalis, et al.
Published: (2020-10-01)

Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis
by: Takako Suzuki, et al.
Published: (2017-06-01)

Denosumab for the treatment of osteoporosis
by: Michael R. McClung
Published: (2017-03-01)

Effect of denosumab on circulating markers of atherosclerosis in women with postmenopausal osteoporosis
by: Cristiana Cipriani, et al.
Published: (2020-10-01)

Update on denosumab in the management of postmenopausal osteoporosis: patient preference and adherence
by: Cairoli E, et al.
Published: (2015-10-01)

Development of protease-activated Denosumab (Prolia) for postmenopausal osteoporosis therapy
by: Ruei-Cheng You, et al.
Published: (2015)

Long-term treatment options for postmenopausal osteoporosis: results of recent clinical studies of Denosumab
by: Zhanna E. Belaya, et al.
Published: (2018-04-01)

Adherence to treatment with denosumab, its efficacy and safety in women with postmenopausal osteoporosis in clinical practice
by: N. V. Toroptsova, et al.
Published: (2016-01-01)

Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis
by: Jiaqi Wu, et al.
Published: (2018-08-01)

A review of denosumab for the treatment of osteoporosis
by: Miyazaki T, et al.
Published: (2014-04-01)

Effects of 3-year denosumab treatment on hip structure in Japanese postmenopausal women and men with osteoporosis
by: Teruki Sone, et al.
Published: (2017-12-01)

Critical appraisal of denosumab in the treatment and prevention of postmenopausal osteoporosis and bone loss in patients undergoing hormone ablation
by: David L Kendler, et al.
Published: (2010-09-01)

Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women
by: Yi Chen, et al.
Published: (2021-04-01)

Osteoporosis in men: epidemiology and treatment with denosumab
by: Sidlauskas KM, et al.
Published: (2014-04-01)

Targeted approaches in the treatment of osteoporosis: differential mechanism of action of denosumab and clinical utility
by: Cavalli L, et al.
Published: (2012-06-01)

Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
by: A. Sánchez, et al.
Published: (2016-01-01)

Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study
by: Masaki Kobayashi, et al.
Published: (2020-03-01)

A randomized placebo-controlled trial of the efficacy of denosumab in Indian postmenopausal women with osteoporosis
by: Shailesh Pitale, et al.
Published: (2015-01-01)

The efficacy and safety of denosumab in postmenopausal women with osteoporosis previously treated with bisphosphonates: A review
by: Yilin Zhu, et al.
Published: (2020-05-01)

High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis
by: Ishikawa K, et al.
Published: (2016-12-01)

Should denosumab treatment for osteoporosis be continued indefinitely?
by: Jane A. Noble, et al.
Published: (2021-04-01)

Denosumab treatment in patients with different courses of osteoporosis
by: Liudmila Ya. Rozhinskaya, et al.
Published: (2017-12-01)

Advantages of using denosumab for osteoporosis
by: O. B. Ershova, et al.
Published: (2013-12-01)

THREE YEARS' EXPERIENCE WITH THE BIOLOGICAL AGENT DENOSUMAB USED TO TREAT WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS: EFFICACY, SAFETY AND TREATMENT ADHERENCE
by: N. V. Toroptsova, et al.
Published: (2017-07-01)

Budget impact analysis of the fentanyl buccal tablet for treatment of breakthrough cancer pain
by: Darbà J, et al.
Published: (2013-12-01)

Denosumab is the first gene engineered agent for the treatment of osteoporosis
by: O A Nikitinskaya, et al.
Published: (2012-09-01)

Phase I/III study to confirm bioequivalence and safe switching of proposed biosimilar denosumab in postmenopausal osteoporosis
by: Jean-Jacques Body, et al.
Published: (2020-10-01)

Denosumab for the treatment of HIV-associated osteoporosis with fractures in a premenopausal woman
by: E. Marasco, et al.
Published: (2021-04-01)

Denosumab for the prevention of osteoporotic fractures in postmenopausal women
by: N Waugh, et al.
Published: (2011-05-01)

Antiresorptive activity of denosumab in the treatment of osteoporosis in patients with rheumatoid arthritis
by: Nadezhda Y. Banshchikova, et al.
Published: (2018-12-01)

Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab
by: Anastasilakis AD, et al.
Published: (2012-06-01)

Cannot write session to /tmp/vufind_sessions/sess_44i6pn8kesnd4u3ki6vcr410uo